Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCT400 + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- Sinocelltech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
**SCT400 + cyclophosphamide + doxorubicin + vincristine + prednisone** is a combination chemotherapy regimen used for the treatment of CD20-positive B-cell non-Hodgkin lymphoma (NHL), particularly diffuse large B-cell lymphoma (DLBCL). SCT400 (also known as ripertamab) is a recombinant chimeric anti-CD20 monoclonal antibody engineered to have enhanced compatibility in the Chinese population and is used as an alternative to rituximab. Cyclophosphamide is an alkylating agent that interferes with DNA replication; doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II; vincristine is a vinca alkaloid that disrupts microtubule formation; prednisone is a synthetic glucocorticoid with anti-inflammatory and lympholytic effects. This combination (SCT400-CHOP, or S-CHOP) is used as a first-line regimen and has demonstrated non-inferior efficacy and safety compared to rituximab-CHOP (R-CHOP) in clinical studies in China. SCT400 specifically targets CD20 on B-cells, leading to cell lysis mainly through complement-dependent and antibody-dependent cellular cytotoxicity.
- Brand names
- Ruipaitai
- Other names
- ripertamab + cyclophosphamide + doxorubicin + vincristine + prednisone
02
Targets
TOP2A (DNA topoisomerase II)CD20 (B-lymphocyte antigen CD20)MicrotubuleGR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on SCT400 + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCT400 + cyclophosphamide + doxorubicin + vincristine + prednisone.